

Republic of Iraq
Ministry of Higher Education
Al-Mustaqbal University
Radiology Techniques Department
Second Stage \ Special Radiological Procedures-1



Lecture No. (3)

Computed Tomography of the Liver and Biliary Tree,

Computed Tomographic Cholangiography

&

Computed Tomography of the Pancreas




By

Dr. Samer Adnan

Computed Tomography of the Liver and Biliary Tree

Indications

1. Suspected focal or diffuse liver lesion
2. **Staging** known primary or secondary malignancy
3. Abnormal liver-function tests
4. Right upper-quadrant pain or mass
5. Hepatomegaly
6. Suspected portal hypertension
7. **Characterization of liver lesion**
8. Pyrexia of unknown origin
9. To facilitate the placement of needles for biopsy
10. Assessment of portal vein, hepatic artery or hepatic veins
11. Assessment of patients with surgical shunts or transjugular intrahepatic portosystemic shunt (TIPS) procedures
12. Follow-up after surgical resection or liver transplant



Contraindications

1. **Pregnancy**
2. **Allergy** to iodinated contrast agents
3. **Impairment of renal function**

Technique

Single-phase (**portal phase**) contrast-enhanced computed tomography

*This is the technique for the majority of **routine liver CT imaging**. The liver is imaged during the peak of parenchymal enhancement-i.e. when contrast-medium-laden portal venous blood has **fully perfused** the liver (around 60–70 s after the start of a bolus injection).

***Oral contrast may be given** **but is not necessary** if only the liver is being investigated.

***Slice thickness** will depend upon the **CT scanner specification** but should be 5 mm or less.

Multiphasic contrast-enhanced computed tomography

*The **fast-imaging times** of **helical/multislice CT** **enable the liver** to be **scanned multiple times** **after a single bolus injection** of contrast medium.

Renal function test

- The following parameters are commonly included in assessing renal function (the normal values/reference range is mentioned)
 - Serum Urea (15-45 mg/dl)
 - Serum Creatinine (0.6 – 1.2 mg/dl)



*Most primary liver tumours receive their blood supply from the hepatic artery, unlike normal hepatic parenchyma, which receives 80% of its **blood supply** from the portal vein.

***Liver tumours** (particularly hypervascular tumours) will therefore **enhance strongly** during the arterial phase (beginning 20–25 s after the start of a bolus injection) but are of similar or lower density to enhanced normal parenchyma during the portal venous phase (washout).





Figure (7). Triphasic of contrast liver CT





Figure (6). Hypervascular lesion is seen in late arterial phase.

*Some tumours are most conspicuous during early-phase arterial scanning (25 s after the start of a bolus injection), and others later, during the late arterial phase 35 s after the start of a bolus IV.

*Thus, a patient who is likely to have **hypervascular primary or secondary liver tumours** should have an **arterial phase** scan **as well as** a **portal venous phase** CT scan (discussed previously).

***Early and late arterial phase with portal venous phase** is appropriate for patients with suspected hepatocellular cancer HCC (**triple phase**).

*Some centres, however, also use a 'delayed' or 'equilibrium' phase scan at 180 s to help identify and characterize primary liver tumours (**quadruple phase**).

***In general**, late arterial and portal venous scans are appropriate to investigate suspected hypervascular metastases.

*Terminology may be **potentially confusing**, as some centres may **consider a triple phase** scan to include arterial, portal and delayed scans. ***Non-contrast** examinations **have limited usefulness**.

Haemangiomas often show a **characteristic peripheral discontinuous nodular enhancement** and progressive centripetal 'fill-in'. After the initial **dual-** or **triple-phase** protocol, delayed images at 5 and 10 min are obtained through the lesion.

Computed Tomographic Cholangiography

Magnetic resonance (MR) cholangiography is **noninvasive** but sometimes fails to display the **normal intrahepatic ducts**. **Multidetector CT cholangiography** can be useful in this instance.


* This technique, the **biliary tree** is **opacified** using an intravenous (i.v) cholangiographic agent.

*Isotropic data from 0.625 mm section thickness slices can be **reconstructed** to provide high-resolution three-dimensional images.

*Insufficient opacification may be seen **with** excessively dilated ducts.

Contraindications



Allergy to iodinated contrast agents.



Indications



1. Screening for cholelithiasis
2. **Preoperative** screening of anatomy
3. Suspected **traumatic bile-duct injury**
4. Other biliary abnormalities—e.g. **cholesterol polyps**, **adenomyomatosis** and **congenital abnormalities**

3D



Technique

1. Patient fasted for at least 6 h.



2. 100 mL i.v. cholangiographic agent—e.g. meglumine iotroxate (biliscopin R) infused for 50 min as a biliary contrast or iodipamide meglumine 52%—20 mL diluted with 80 mL of **normal saline** infused over 30 min.
3. CT scan should be obtained at least 35 min **after** infusion of contrast agent.

Computed Tomography of the Pancreas

Indications

1. **Epigastric pain**
2. Obstructive jaundice

3. Suspected **pancreatic malignancy**
4. **Acute pancreatitis** and its **complications**
5. **Chronic pancreatitis** and its **complications**

Contraindications

1. Pregnancy
2. Allergy to iodinated contrast agents

Technique

1. **Negative** (e.g. **water**) **oral** contrast is generally **preferred**.

***Positive** (e.g. **iodinated**) **oral contrast** may be given if necessary to **opacify distal bowel loops** but is **contraindicated** if **CT angiography** is to be performed.

***Volume** and **timing of oral contrast** agent will **depend upon** whether **opacification of distal bowel loops** is required.

2. **Venous access** is obtained.

3. The patient is scanned **supine** and a **scout view** is obtained.

4. An **initial non-contrast-enhanced** examination to identify **calcification** is **no** longer indicated, as this will be **evident** on **vascular** phases.

5. The **volume** and **strength** of the **i.v. contrast** will *depend upon* the **speed of the scanner**.


*The volume of i.v. contrast usually varies from 100 to 150 mL s⁻¹ of **iodinated** contrast at 3–4 mL s⁻¹, with a **saline chaser**, depending on the scanner type.

*Pancreatic parenchymal phase enhancement (35–40 s after commencement of bolus injection) is necessary for optimum contrast differentiation between **pancreatic adenocarcinoma** and **normal pancreatic tissue**, with portal venous phase scans (65–70 s after onset of the injection) included in the protocol to investigate hepatic metastatic disease.

*Images should be **reconstructed** at 0.625–1.25 mm in the pancreatic phase and 2 mm in the portal venous phase.

6. Islet cell tumours and their metastases may show **avid enhancement** on arterial phase scans and become **isodense** with normal pancreatic tissue on portal phase scans.

*A portal phase scan is generally **necessary** to investigate flow and the relationship of the tumour to the portal vein.



1. native
2. non contrast
3. without contrast
4. pre contrast

فحص بدون او قبل الصبغة




Figure (1). Normal liver CT




Figure (2). Normal liver CT




Figure (4). Normal liver CT

